Capital Investment Advisors LLC Has $7.20 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Capital Investment Advisors LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 12.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,450 shares of the medical research company’s stock after buying an additional 3,554 shares during the quarter. Capital Investment Advisors LLC’s holdings in Amgen were worth $7,204,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Platform Technology Partners raised its position in shares of Amgen by 0.8% during the 1st quarter. Platform Technology Partners now owns 5,315 shares of the medical research company’s stock valued at $1,285,000 after acquiring an additional 41 shares during the last quarter. Apeiron RIA LLC raised its position in shares of Amgen by 2.3% during the 1st quarter. Apeiron RIA LLC now owns 1,842 shares of the medical research company’s stock valued at $446,000 after acquiring an additional 42 shares during the last quarter. All Terrain Financial Advisors LLC raised its position in shares of Amgen by 0.8% during the 1st quarter. All Terrain Financial Advisors LLC now owns 5,646 shares of the medical research company’s stock valued at $1,365,000 after acquiring an additional 44 shares during the last quarter. LifeSteps Financial Inc. raised its position in shares of Amgen by 3.4% during the 1st quarter. LifeSteps Financial Inc. now owns 1,373 shares of the medical research company’s stock valued at $332,000 after acquiring an additional 45 shares during the last quarter. Finally, First United Bank & Trust raised its position in shares of Amgen by 0.7% during the 1st quarter. First United Bank & Trust now owns 6,345 shares of the medical research company’s stock valued at $1,534,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 74.44% of the company’s stock.

Insider Buying and Selling

In related news, EVP Murdo Gordon sold 9,558 shares of Amgen stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $262.43, for a total transaction of $2,508,305.94. Following the completion of the transaction, the executive vice president now owns 44,308 shares in the company, valued at $11,627,748.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Amgen Stock Down 0.6 %

Shares of NASDAQ AMGN traded down $1.58 during mid-day trading on Friday, hitting $260.72. The company had a trading volume of 6,161,175 shares, compared to its average volume of 2,463,185. The company has a market capitalization of $139.46 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 3.23 and a beta of 0.61. The firm has a 50-day simple moving average of $248.12 and a two-hundred day simple moving average of $237.71. The company has a current ratio of 2.77, a quick ratio of 2.48 and a debt-to-equity ratio of 8.76. Amgen Inc. has a one year low of $211.71 and a one year high of $296.67.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $5.00 earnings per share for the quarter, beating the consensus estimate of $4.44 by $0.56. The company had revenue of $7 billion during the quarter, compared to analysts’ expectations of $6.66 billion. Amgen had a return on equity of 196.60% and a net margin of 30.02%. Amgen’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the company earned $4.65 EPS. On average, equities analysts expect that Amgen Inc. will post 18.35 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Friday, August 18th were issued a dividend of $2.13 per share. This represents a $8.52 dividend on an annualized basis and a yield of 3.27%. The ex-dividend date was Thursday, August 17th. Amgen’s payout ratio is currently 57.45%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on AMGN shares. Mizuho upped their price objective on shares of Amgen from $214.00 to $223.00 and gave the company a “neutral” rating in a research report on Monday, August 14th. Credit Suisse Group lowered their price objective on shares of Amgen from $220.00 to $200.00 in a research report on Wednesday, July 12th. HSBC started coverage on shares of Amgen in a research report on Wednesday, September 6th. They issued a “buy” rating and a $320.00 price objective for the company. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 8th. Finally, Oppenheimer restated an “outperform” rating and issued a $280.00 price objective on shares of Amgen in a research report on Tuesday, July 25th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $264.19.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.